|Other names||BGS-649; CGP-47645|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||303.300 g·mol−1|
|3D model (JSmol)|
Leflutrozole (developmental code names BGS-649, CGP-47645) is an aromatase inhibitor which is under development by Mereo BioPharma and Novartis for the treatment of hypogonadism in men. It was also under investigation for the treatment of endometriosis, but development for this indication was discontinued. As of December 2017, leflutrozole is in phase II clinical trials for hypogonadism.